Vermont’s Heralded Drug Prices Transparency Bill Disappoints Nearly Two Years In

“We took a first step toward transparency, but it wasn’t substantial enough to give us anything of true value," said Vermont state lawmaker William Lippert. In other news FDA Commissioner Scott Gottlieb wants to get biosimilars to the market faster, and Democrats prepare to use high drug prices as a campaign message.

from Kaiser Health News https://ift.tt/2pOaYwe